Welcome to our dedicated page for Defence Therapeu news (Ticker: DTCFF), a resource for investors and traders seeking the latest updates and insights on Defence Therapeu stock.
Defence Therapeutics Inc. reports developments in biotechnology and precision intracellular drug delivery through its proprietary Accum® platform. Company news centers on cancer-therapy applications, including antibody-drug conjugates, radiopharmaceutical and radio-immunoconjugate programs, and other complex biologics designed for intracellular and nuclear delivery.
Recurring updates also cover scientific advisory activity, industry presentations, collaboration work such as its program with Canadian Nuclear Laboratories, partnership outreach, and capital-structure actions including private placements, warrant amendments, and restricted stock unit grants.
Defence Therapeutics (OTCQB:DTCFF) will participate in the BIO International Convention 2026 in San Diego from June 22-25. The company plans strategic partnership discussions focused on its Accum® intracellular delivery platform for ADCs, radiopharmaceuticals, biosimilars, and revitalizing existing or discontinued therapeutic assets.
Defence Therapeutics (OTCQB:DTCFF) appointed biopharma executive Dr John Beaver to its Board of Directors. He brings 20+ years of leadership at Biogen, AbbVie, and GlaxoSmithKline, spanning translational medicine, biomarkers, and clinical pharmacology.
Defence granted Dr Beaver 150,000 stock options, vested immediately at $0.60 per share for five years, and continues advancing its ACCUM® intracellular delivery platform across ADC and radiopharmaceutical programs.
Defence Therapeutics (OTCQB:DTCFF) appointed ADC pioneer Dr. John Lambert to its Board of Directors, effective immediately. Lambert brings 40+ years of antibody-drug conjugate experience, including leadership roles at ImmunoGen, whose ADC technologies contributed to therapies such as KADCYLA, SARCLISA and ELAHERE.
Defence granted Lambert 150,000 stock options, vesting immediately and exercisable at $0.58 per share for five years. The company continues advancing its ACCUM-enabled ADC and radiopharmaceutical programs to enhance intracellular delivery and treatment outcomes.
Defence Therapeutics (OTCQB:DTCFF) announced that Dr. Sarkis Meterissian resigned from its Board of Directors to join the company’s Scientific Advisory Board (SAB). The SAB now includes Rob Leanna, PhD, Danny Chui, PhD, Brendan Hussey, PhD, and Dr. Meterissian.
The company also granted 150,000 incentive stock options to employees and consultants under its omnibus incentive plan, vested immediately and exercisable at $0.58 per share for five years from the grant date.
Defence Therapeutics (OTCQB:DTCFF) announced expanded in-house capabilities for its ACCUM®-enabled antibody-drug conjugate (ADC) development platform. The company strengthened purification, analytical characterization, conjugation development, and quality control, and enhanced cellular testing using new systems, within a structured, stage-gated framework to support ADC partnership programs and lead-candidate selection.
Defence Therapeutics (OTCQB: DTCFF) announced that its board approved a grant of 200,000 incentive restricted stock units (RSUs) to CEO and director Sebastien Plouffe, vesting immediately on April 24, 2026. Each RSU converts to one common share and expires April 24, 2027, subject to the Omnibus Incentive Plan and securities law hold periods.
Defence Therapeutics (OTCQB: DTCFF) announced an amendment to 800,000 Common Share purchase warrants issued in a 2024 private placement.
The amendment extends each warrant expiry by 12 months and reprices the exercise price to $0.75 per share (from $1.00). The split is 775,000 and 25,000 warrants with new expiries of October 30, 2027 and November 29, 2027 respectively. None have been exercised. All other warrant terms remain unchanged and the changes are subject to final approval of the Canadian Securities Exchange; compensation and finder warrants are not eligible for amendment.
Defence Therapeutics (OTCQB: DTCFF) closed a private placement of 17,445,455 Units at $0.55 per Unit for aggregate gross proceeds of $9,595,000.25 on March 6, 2026. Each Unit includes one common share and one Warrant exercisable at $0.65 per share for 24 months.
The Company received $6,000,000 from two institutional investors under a binding term sheet; those 10,909,091 Warrants contain a 9.99% equity blocker. Investors received a corporate finance fee of 654,546 Units and a non-refundable deposit of 118,182 Units. Proceeds will fund ADC and radiopharmaceutical programs, partnerships, and working capital.
Defence Therapeutics (OTCQB:DTCFF) will showcase its proprietary Accum intracellular delivery platform at multiple international life‑science events in March 2026, including BIO‑Europe Spring (Mar 23‑26, Lisbon) and DCAT Week (Mar 23‑26, New York).
The company will pursue strategic partnerships, biomanufacturing discussions, and U.S. investor outreach at additional events in Miami (Mar 24) and FII PRIORITY Miami (Mar 25‑27), and has joined DCAT and BioFlorida to support commercial readiness for Accum.
Defence Therapeutics (OTCQB:DTCFF) launched a private placement of up to 20,000,000 Units at $0.55 for aggregate gross proceeds up to $11,000,000. Each Unit includes one share and one warrant exercisable at $0.65 for 24 months.
The company executed a binding term sheet for $6,000,000 CAD from two institutional investors with proceeds held in escrow and released as monthly cash tranches of $333,333 CAD over 18 months, subject to a sharing agreement that ties monthly share releases to a $0.7332 CAD benchmark price.